Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amira Pharmaceuticals (Amira) has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline (GSK) related to the successful development of a solid dose formulation.
Subscribe to our email newsletter
Hari Kumar, chief business officer of Amira Pharmaceuticals, said: “Achieving this milestone further demonstrates the success of our partnership with GSK and provides a meaningful economic benefit to Amira. We are very pleased with our partnership and look forward to the continued success of this program at GSK.”
FLAP (5-lipoxygenase activating protein) is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity.
Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM103 and AM803 bind to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation.
Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of new compounds and effective pre-clinical and clinical program decisions.